

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 1844-US-WO		Int'l Appln No: PCT/GB03/003951
	Applicant: Alan Crossman et al.		
	Filing Date: March 8, 2005	Group Art Unit: 1617	

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,452,808	06/1984	Gallagher, Jr.			
	4,513,006	04/1985	Maryanoff et al.			
	4,582,916	04/1986	Maryanoff et al.			
	4,824,860	04/1989	Owen			
	6,420,369	07/2002	Marcotte			
	6,559,293	05/2003	Almarsson et al.			
	6,583,172	06/2003	Shank			
	6,649,607	11/2003	Leventer et al.			

FOREIGN PATENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
	0138441	08/1988	EP			
	99/06408	02/1999	WO			
	00/61138	10/2000	WO			
	01/04122	01/2001	WO			
	02/064085	08/2002	WO			

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Abuzzahab et al., "Control of Tourette's Syndrome with Topiramate", American Journal of Psychiatry, Vol. 158, No. 6, June 2001, pg. 968, XP009022623.
	Abuzzahab et al., "Topiramate for Clozapine-Induced Seizures", American Journal of Psychiatry, American Psychiatric Association, Washington, D.C., Vol. 158, No. 6, June 2001, pp. 968-969, XP001095768.
	Blanchet et al., "Differing Effects of N-Methyl-D-Aspartate Receptor Subtype Selective Antagonists on Dyskinesias in Levodopa-Treated 1-Methyl-4-Phenyl-Tetrahydropyridine Monkeys," JPET, vol. 290, no. 3, 1999, pp. 1034-1040.
	Burne et al., "The Contribution of Tremor Studies to Diagnosis of Parkinsonian and Essential Tremor: A Statistical Evaluation," Journal of Clinical Neuroscience, vol. 9, no. 3, 2002, pp. 237-242.
	Connor, "A Double-Blind Placebo-Controlled Trial of Topiramate Treatment for Essential Tremor," Neurology, 59, 2002, pp. 132-134.
	Coppola et al., "Topiramate as Add-On Drug in Severe Myoclonic Epilepsy in Infancy: An Italian Multicenter Open Trial", Epilepsy Research, Vol. 49, No. 1, March 2002, pp. 45-48, XP002264038.
	Dursun et al., "Clozapine Weight Gain, Plus Topiramate Weight Loss", Canadian Journal of Psychiatry, Revue Canadienne de Psychiatrie, Canadian Psychiatric Association, Ottawa, CA, Vol. 45, No. 2, March 2000, pg. 198, XP001097327.
	Fox et al., "Neural Mechanisms Underlying Peak-Dose Dyskinesia Induced by Levodopa and Apomorphine are Distinct: Evidence from the Effects of the Alpha ₂ Adrenoceptor Antagonist Idazoxan," Movement Disorders, vol. 16, no. 4, 2001, pp. 642-650.

EXAMINER: /Sahar Javanmard/	DATE CONSIDERED: 12/11/2009
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	Docket Number: 184.4-US-WO	Int'l Appln No.: PCT/GB03/003951 Int'l Filing Date: 11 Sept 2003
	Applicant: Alan Crossman et al.	
	Filing Date: March 8, 2005	Group Art Unit: 1617

	Henry et al., "μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease," <i>Experimental Neurology</i> , 171, 2001, pp. 139-146.
	Kanda et al., "Combined Use of the Adenosine A _{2A} Antagonist KW-6002 with L-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity by Not Dyskinesia in MPTP-Treated Monkeys," <i>Experimental Neurology</i> , 162, 2000, pp. 321-327.
	Kellett et al., "Topiramate in Clinical Practice: First Year's Postlicensing Experience in a Specialist Epilepsy Clinic", <i>Journal of Neurology Neurosurgery and Psychiatry</i> , Vol. 66, No. 6, June 1999, pp. 759-763, XP002264039.
	Levine, "Medical Treatment of Essential Tremor and Parkinson's Disease," <i>Geriatrics</i> , vol. 53, issue 5, May 1998, 10 pages.
	Nash et al., "Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease," <i>Experimental Neurology</i> , 165, 2000, pp. 136-142.
	Skradski et al., "Topiramate Blocks Kainate-Evoke Cobalt Influx into Cultured Neurons," <i>Epilepsia</i> , 41 (Suppl. 1), 2000, pp. S45-S47.
	Wolters et al., "Parkinson's Disease," <i>Recent Advances in Pharmacotherapy, CMAJ</i> , vol. 140, March 1, 1989, pp. 507-513.
	Answers.com, dyskinesia, http://www.answers.com/topic/dyskinesia , printed 09/11/2008, 4 pages.

EXAMINER: /Sahar Javanmard/	DATE CONSIDERED: 12/11/2009
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE